Albumin-binding domain conjugate for near-infrared fluorescence lymphatic imaging

Molecular Imaging and Biology

Volumn 14, Issue 3, 2012, Pages 301-314

  Davies Venn, Cynthia A ^a,b   Angermiller, Bonnie ^a   Wilganowski, Nathaniel ^a   Ghosh, Pradip ^a   Harvey, Barrett R ^a   Wu, Grace ^a   Kwon, Sunkuk ^a   Aldrich, Melissa B ^a   Sevick Muraca, Eva M ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Albumin peptide conjugate; Lymphatic imaging; Near infrared fluorescence

Indexed keywords

AGENTS USED IN FUNCTION TESTS; CYCLIC ALBUMIN BINDING DOMAIN PEPTIDE FLUORESCENT DYE CONJUGATE; INDOCYANINE GREEN; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; BINDING ASSAY; DRUG CLEARANCE; DRUG STRUCTURE; FEMALE; FLUORESCENCE IMAGING; IC 50; LYMPHATIC SYSTEM; MOUSE; NEAR INFRARED FLUORESCENCE IMAGING; NON INVASIVE PROCEDURE; NONHUMAN; PARTITION COEFFICIENT; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN STABILITY; PROTEIN TRANSPORT;

ALBUMINS; ANIMALS; BINDING SITES; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FLUORESCENT DYES; HUMANS; INDOCYANINE GREEN; LYMPHATIC VESSELS; MICE; MICE, INBRED C57BL; PEPTIDES; PROTEIN BINDING; SPECTROMETRY, FLUORESCENCE; SPECTROSCOPY, NEAR-INFRARED;

MUS;

EID: 84858798644     PISSN: 15361632     EISSN: 18602002     Source Type: Journal    
DOI: 10.1007/s11307-011-0499-x     Document Type: Article

References (59)

1. Rockson SG (2001) Lymphedema. Am J Med 110:288-295
2. Alitalo K, Tammela T, Petrova TV (2005) Lymphangiogenesis in development and human disease. Nature 438:946-953 (Pubitemid 43093960)
3. Ferrell RE, Levinson KL, Esman JH et al (1998) Hereditary lymphedema: evidence for linkage and genetic heterogeneity. Hum Mol Genet 7:2073-8 (Pubitemid 28546416)
4. Irrthum A, Karkkainen MJ, Devriendt K, Alitalo K, Vikkula M (2000) Congenital hereditary lymphedema caused by a mutation that inactivates VEGFR3 tyrosine kinase. Am J Hum Genet 67:295-301 (Pubitemid 30616736)
5. Irrthum A, Devriendt K, Chitayat D et al (2003) Mutations in the transcription factor gene SOX18 underlie recessive and dominant forms of hypotrichosis-lymphedema-telangiectasia. Am J Hum Genet 72:1470-8 (Pubitemid 36628386)
6. Fang J, Dagenais SL, Erickson RP et al (2000) Mutations in FOXC2 (MFH-1), a forkhead transcription factor are responsible for hereditary lymphedema-distichiasis syndrome. Am J Hum Genet 67:1382-1388
7. Lyon MF, Glenister PH (1984) Mouse News Lett 71:26
8. Karkkainen MJ, Saaristo A, Jussila L et al (2001) Model for gene therapy for human hereditary lymphedema. PNAS 23:12677-82 (Pubitemid 33020005)
9. Francois M, Caprini A, Hosking B et al (2008) Sox18 induces development of lymphatic vasculature in mice. Nature 456:643-7
10. Kriederman BM, Myloyde TL, Witte MH et al (2003) FOXC2 haploinsufficient mice are a model for human autosomal dominant lymphedema-distichiasis syndrome. Hum Mol Genet 10:1179-1185 (Pubitemid 36622150)
11. Finegold DN, Schacht V, Kimak MA et al (2008) HGF and MET mutations in primary and secondary lymphedema. Lymphat Res Biol 6:65-8 (Pubitemid 351873446)
12. Sharma R, Wendt JA, Rasmussen JC, Adams KE, Marshall MV, Sevick-Muraca EM (2008) New horizons for imaging lymphatic function. Ann NY Acad Sci 1131:13-36 (Pubitemid 351758500)
13. Szuba A, Shin WS, Strauss HW, Rockson S (2003) The third circulation: radionuclide scintigraphy in the evaluation of lymphedema. J Nucl Med 44:43-57 (Pubitemid 36077712)
14. Yuan Z, Chen L, Luo Q, Zhu J, Lu H, Zhu R (2006) The role of radionuclide lymphoscintigraphy in extremity lymphedema. Ann Nucl Med 20:341-344 (Pubitemid 44099124)
15. Witte CL, Witte MH, Unger EC et al (2000) Advances in imaging of lymph flow disorders. Radiographics 20:1697-719
16. Marotel M, Cluzan R, Ghabboun S, Pascot M, Alliot F, Lasry JL (1998) Transaxial computer tomography of lower extremity lymphedema. Lymphology 31:180-85 (Pubitemid 29056711)
17. Lohrmann C, Foeldi E, Langer M (2009) MR imaging of the lymphatic system in patients with lipedema and lipo-lymphedema. Microvasc Res 77:335-9
18. Marshall MV, Rasmussen JC, Tan I-C et al (2010) Near-infrared fluorescence imaging in humans with indocyanine green: a review and update. Open Surg Oncol J 2:12-25
19. Craandijk A, Van Beek CA (1976) Indocyanine green fluorescence angiography of the choroid. Brit J Opthal 60:377-85
20. Cherrick GR, Stein SW, Leevy CM, Davidson CS (1960) Indocyanine Green: observations on its physical properties, plasma decay and hepatic extraction. J Clin Investig 39:592-600
21. Sevick-Muraca, EM, Sharma R, Rasmussen JC et al. (2008) Imaging of lymph flow in breast cancer patients after microdose administration of a near-infrared fluorophore. Radiology 246:734-741
22. Rasmussen JC, Tan I-C, Marshall MV, Fife CE, Sevick-Muraca EM (2009) Lymphatic imaging in humans with near-infrared fluorescence. Curr Opin Biotechnol 20:1-9
23. Maus EA, Tan I-C, Rasmussen JC et al. (2010) Near-infrared fluorescence lymphatic imaging of head and neck lymphedema. Head and Neck PMID: 21077150
24. Adams KE, Rasmussen JC, Darne C et al (2010) A method to assess lymphatic response to advanced pneumatic compression device treatment of lymphedema. Biomed Opt Express 1:114-125
25. Rasmussen JC, Tan I-C, Maus EA et al (2010) Human lymphatic architecture and dynamic transport imaged using near-infrared fluorescence. Transl Oncol 3:362-72
26. Tan I-C, Maus EA, Rasmussen JC et al (2011) NIR fluorescence imaging of improved lymphatic propulsion and transport following manual lymphatic drainage. Arch Phys Med Rehabil (in press)
27. Saxena V, Sadoqi M, Shao J (2003) Degradation kinetics of indocyanine green in aqueous solution. J Pharm Sci 92:2090-97 (Pubitemid 37175639)
28. Philip R, Penzkofer A, Baumler W, Szeimies RM, Abels C (1996) Absorption and fluorescence spectroscopic investigation of indocyanine green. J Photochem Photobiol A 96:137-38
29. Landsmen ML, Kwant G, Mook GA, Zijlstra WG (1976) Lightabsorbing properties, stability and spectral stabilization of Indocyanine green. J Appl Physiol 40:575-583
30. Fiehn C, Kratz F, Sass G, Muller-Ladner U, Neumann E (2008) Targeted drug delivery by in vivo coupling to endogenous albumin: an albumin-binding prodrug of methotrexate (MTX) is better than MTX in the treatment of murine collagen-induced arthritis. Ann Rheum Dis 67:1188-91
31. Xie D, Yao C, Wang L et al (2010) An albumin conjugated peptide exhibits potent anti-HIV activity and long in vivo half- life. Antimicrob Agents Chemother 54:191-6
32. Chen K, Xie J, Chen X (2009) RGD-human serum albumin conjugates as efficient tumor targeting probes. Mol Imaging 8:65-73
33. 12,14 prostaglandin-J2 in vivo. Neoplasia 11:1348-58
34. Lo et al (2011) Targeted human serum albumin nanoparticles for uptake in EGFR colon carcinoma. Nanomedicine (in press)
35. Dubey PK, Singodia D, Verma RK, Vyas SP (2011) RGD modified albumin nanospheres for tumor vasculature targeting. J Pharm Pharmacol 63:33-40
36. Anhorn MG, Wagner S, Kreuter J, Langer K, von Briesen H (2008) Specific targetting of HER2 overexpressing breast cancer cells with human serum albumin nanoparticles. Biconjugate Chem 19:2321-31
37. Kratz F, Mueller-Driver R, Hofmann I, Drevs J, Unger C (2000) A novel macromolecular prodrug concept exploiting endogenous serum albumin as a drug carrier for cancer chemotherapy. J Med Chem 43:1253-1256 (Pubitemid 30212566)
38. Linhult M, Binz HK, Uhlén M, Hober S (2002) Mutational analysis of interaction between albumin binding domain from streptococcal G protein and serum albumin. Protein Sci 11:206-213 (Pubitemid 34075783)
39. Johansson (2002) Structure, specificity and mode of action for bacterial albumin binding modules. J Biol Chem 277:8114-20
40. Dennis M, Zhang M, Meng YG (2002) Albumin binding as a general strategy for improving the pharmacokinetics of proteins. J Biol Chem 277:35035-43
41. Nguyen A, Reyes A, Zhang M et al (2006) The pharmacokinetics of an albumin-binding Fab (AB.Fab) can be modulated as a function of albumin binding. Protein Eng Des Sel 19:291-297 (Pubitemid 43999639)
42. Stork R, Muller E, Kontermann RE (2007) A novel tri-functional antibody fusion protein with improved pharmacokinetic properties generated by fusing a bispecific single-chain diabody with an albumin binding domain from Streptococcal protein G. Protein Eng Des Sel 20:569-76 (Pubitemid 350176487)
43. Müller D, Karle A, Meissburger B, Höfig I, Stork R, Kontermann RE (2007) Improved pharmacokinetics of recombinant bispecific antibody molecules by fusion to human serum albumin. JBC 282:12650-60 (Pubitemid 47100581)
44. Anhorn MG, Wagner S, Kreuter J, Langer K, von Briesen H (2008) Specific targeting of HER2 overexpressing breast cancer cells with doxorubicin-loaded, trastuzumab modified human serum albumin nanoparticles. Bioconjug Chem 19:2321-31
45. Jonsson A, Dogan J, Herne N, Abrahmsén L, Nygren PA (2008) Engineering of a femtomolar affinity binding protein to human serum albumin. Prot Eng Des Sel 21:515-27 (Pubitemid 352019923)
46. Trussel S, Dumelin C, Frey K, Villa A, Buller F, Neri D (2009) New strategy for the extension of the half-life of antibody fragments. Bioconjug Chem 20:2286-92
47. Hopp J, Hornig N, Zettlitz KA et al (2010) Effects of affinity and valency of albumin binding domain on half life. Protein Eng Des Sel 23:827-34
48. Sebak S, Mirzaei M, Malhotra M, Kulamarva A, Prakash S (2010) Human serum albumin nanoparticles as an efficient noscapine drug delivery system for potential use in breast cancer: preparation and in vitro analysis. Int J Nanomedicine 5:525-32
49. Vandoorne K, Addadi Y, Neeman M (2010) Visualizing vascular permeability and lymphatic drainage using labeled serum albumin. Angiogenesis 13:75-85
50. Andersen JT, Pehrson R, Tolmachev V, Daba MB, Abrahmsén L, Ekblad C (2011) Extending half-life by indirect targeting of the neonatal Fc receptor (FcRN) using a minimal albumin binding domain. J Biol Chem 286:5234-41
51. Marshall MV, Draney D, Sevick-Muraca EM, Olive DM (2010) Single dose toxicity study of IRDye800 CW in Spraque-Dawley rats. Mol Imaging Biol 12:583-94
52. Williams ATR, Winfield SA, Miller JN (1983) Relative fluorescence quantum yields using a computer controlled luminescence spectrometer. Analyst 108:1067
53. Sevick-Muraca EM, Lopez G, Reynolds JS, Troy TL, Hutchinson CL (1997) Fluorescence and absorption contrast mechanisms for biomedical optical imaging using frequency domain techniques. Photochem Photobiol 66:55-64 (Pubitemid 127470633)
54. Yuk JS, Trnavsky M, McDonagh C, MacCraith B (2010) Surface plasmon-coupled emission (SPCE)-based immunoassay using a novel paraboloid array biochip. Biosens Bioelectron 25:1344-49
55. Holzer W, Mauerer M, Penzkofer A et al (1998) Photostability and thermal stability of indocyanine green. J Photochem Photobiol B 47:155-64 (Pubitemid 29108043)
56. Ohnishi S, Lomnes SJ, Laurence RG, Gogbashian A, Mariani G, Frangioni JV (2005) Organic alternatives to quantum dots for intraoperative near-infrared fluorescent sentinel lymph node mapping. Mol Imaging 4:172-181 (Pubitemid 43143790)
57. Maarek JM, Holschneider DP, Harimoto J (2000) Fluorescence of indocyanine green in blood: intensity dependence on concentration and stabilization with sodium polyaspartate. J Photochem Photobiol B 65:157-64 (Pubitemid 34110732)
58. Ott P, Weisiger RA (1997) Nontraditional effects of protein binding and hematocrit on uptake of indocyanine green by perfused rat liver. Am J Physiol 273:G227-38
59. Kwon S, Sevick-Muraca EM (2010) Functional lymphatic imaging in tumor-bearing mice. J Immunol Meth 360(1-2):167-172